Sarepta Theraps Inc Drug Patent Portfolio
Sarepta Theraps Inc owns 3 orange book drugs protected by 27 US patents Given below is the list of Sarepta Theraps Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10337003 | Compositions for treating muscular dystrophy | 14 Mar, 2034 | Active |
| US10364431 | Compositions for treating muscular dystrophy | 14 Mar, 2034 | Active |
| US9506058 | Compositions for treating muscular dystrophy | 14 Mar, 2034 | Active |
| US10287586 | Antisense molecules and methods for treating pathologies | 12 Nov, 2030 | Active |
| US10781450 | Antisense molecules and methods for treating pathologies | 12 Nov, 2030 | Active |
| US9228187 | Antisense molecules and methods for treating pathologies | 12 Nov, 2030 | Active |
| US9758783 | Antisense molecules and methods for treating pathologies | 12 Nov, 2030 | Active |
| USRE47769 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 02 Feb, 2029 | Active |
| US9243245 | Means and methods for counteracting muscle disorders | 27 Oct, 2028 | Active |
| USRE48468 | Means and methods for counteracting muscle disorders | 27 Oct, 2028 | Active |
| USRE47691 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 28 Jun, 2028 | Active |
| US8524880 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 02 Apr, 2026 | Active |
| US9447415 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 28 Jun, 2025 | Active |
| USRE48960 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 28 Jun, 2025 | Active |
| US10781451 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 28 Jun, 2025 | Active |
| US8486907 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 28 Jun, 2025 | Active |
| US9018368 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 28 Jun, 2025 | Active |
| USRE47751 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 28 Jun, 2025 | Active |
| US10227590 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 28 Jun, 2025 | Active |
| US10266827 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 28 Jun, 2025 | Active |
| US10421966 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 28 Jun, 2025 | Active |
| US10968450 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 28 Jun, 2025 | Active |
| US10995337 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 28 Jun, 2025 | Active |
| US9024007 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 28 Jun, 2025 | Active |
| US9994851 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | 28 Jun, 2025 | Active |
| US10533174 | Splice-region antisense composition and method | 04 May, 2021 | Expired |
| US9416361 | Splice-region antisense composition and method | 04 May, 2021 | Expired |
Latest Legal Activities on Sarepta Theraps Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sarepta Theraps Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 May, 2024 | US9506058 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Mar, 2024 | US10781450 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Mar, 2024 | US10781451 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Mar, 2024 | US9447415 |
|
Withdrawal of Application for PTE
Critical
| 07 Mar, 2024 | US10266827 |
|
Withdrawal of Application for PTE
Critical
| 07 Mar, 2024 | US9994851 |
|
Withdrawal of Application for PTE
Critical
| 07 Mar, 2024 | US10421966 |
|
Withdrawal of Application for PTE
Critical
| 07 Mar, 2024 | US10227590 |
|
Withdrawal of Application for PTE
Critical
| 07 Mar, 2024 | US9024007 |
|
Expire Patent
Critical
| 19 Feb, 2024 | US10533174 |
|
Expire Patent
Critical
| 19 Feb, 2024 | US10533174 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US8524880 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US10287586 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US10781450 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US9228187 |
Sarepta Theraps Inc's Drug Patent Litigations
Sarepta Theraps Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 29, 2015, against patent number US8486907. The petitioner , challenged the validity of this patent, with Stephen Donald Wilton et al as the respondent. Click below to track the latest information on how companies are challenging Sarepta Theraps Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8486907 | September, 2015 |
Decision
(29 Sep, 2015)
| Stephen Donald Wilton et al | |
Sarepta Theraps Inc Drug Patents' Oppositions Filed in EPO
Sarepta Theraps Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 24, 2015, by Howard Wright/ Nicholas Wallin/ Withers & Rogers Llp. This opposition was filed on patent number EP09788160A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP17171389A | Jan, 2023 | Maiwald GmbH | Granted and Under Opposition |
| EP17171389A | Jan, 2023 | Bosch Jehle Patentanwaltsgesellschaft mbH | Granted and Under Opposition |
| EP13160338A | Oct, 2016 | Withers & Rogers LLP/Wright Howard/Wallin Nicholas | Revoked |
| EP08842559A | Sep, 2016 | Withers & Rogers LLP | Revoked |
| EP10004274A | Aug, 2016 | Nippon Shinyaku Co., Ltd. | Revoked |
| EP09788160A | Sep, 2015 | Howard Wright/ Nicholas Wallin/ Withers & Rogers LLP | Patent maintained as amended |
Sarepta Theraps Inc's Family Patents
Sarepta Theraps Inc Drug List
Given below is the complete list of Sarepta Theraps Inc's drugs and the patents protecting them.
1. Amondys 45
Amondys 45 is protected by 9 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10287586 | Antisense molecules and methods for treating pathologies |
12 Nov, 2030
(5 years from now)
| Active |
| US10781450 | Antisense molecules and methods for treating pathologies |
12 Nov, 2030
(5 years from now)
| Active |
| US9228187 | Antisense molecules and methods for treating pathologies |
12 Nov, 2030
(5 years from now)
| Active |
| US9758783 | Antisense molecules and methods for treating pathologies |
12 Nov, 2030
(5 years from now)
| Active |
| US8524880 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
02 Apr, 2026
(1 year, 3 months from now)
| Active |
| US9447415 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
28 Jun, 2025
(6 months from now)
| Active |
| USRE48960 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
28 Jun, 2025
(6 months from now)
| Active |
| US10533174 | Splice-region antisense composition and method |
04 May, 2021
(3 years ago)
| Expired |
| US9416361 | Splice-region antisense composition and method |
04 May, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Amondys 45's drug page
2. Exondys 51
Exondys 51 is protected by 12 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10337003 | Compositions for treating muscular dystrophy |
14 Mar, 2034
(9 years from now)
| Active |
| US10364431 | Compositions for treating muscular dystrophy |
14 Mar, 2034
(9 years from now)
| Active |
| US9506058 | Compositions for treating muscular dystrophy |
14 Mar, 2034
(9 years from now)
| Active |
| USRE47769 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
02 Feb, 2029
(4 years from now)
| Active |
| US9243245 | Means and methods for counteracting muscle disorders |
27 Oct, 2028
(3 years from now)
| Active |
| USRE48468 | Means and methods for counteracting muscle disorders |
27 Oct, 2028
(3 years from now)
| Active |
| US10781451 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
28 Jun, 2025
(6 months from now)
| Active |
| US8486907 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
28 Jun, 2025
(6 months from now)
| Active |
| US9018368 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
28 Jun, 2025
(6 months from now)
| Active |
| USRE47751 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
28 Jun, 2025
(6 months from now)
| Active |
| US10533174 | Splice-region antisense composition and method |
04 May, 2021
(3 years ago)
| Expired |
| US9416361 | Splice-region antisense composition and method |
04 May, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exondys 51's drug page
3. Vyondys 53
Vyondys 53 is protected by 10 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| USRE47691 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
28 Jun, 2028
(3 years from now)
| Active |
| US10227590 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
28 Jun, 2025
(6 months from now)
| Active |
| US10266827 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
28 Jun, 2025
(6 months from now)
| Active |
| US10421966 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
28 Jun, 2025
(6 months from now)
| Active |
| US10968450 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
28 Jun, 2025
(6 months from now)
| Active |
| US10995337 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
28 Jun, 2025
(6 months from now)
| Active |
| US9024007 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
28 Jun, 2025
(6 months from now)
| Active |
| US9994851 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
28 Jun, 2025
(6 months from now)
| Active |
| US10533174 | Splice-region antisense composition and method |
04 May, 2021
(3 years ago)
| Expired |
| US9416361 | Splice-region antisense composition and method |
04 May, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vyondys 53's drug page